FIGURE 2.

Prognostic gene-signature risk score validation in an independent dataset. A, Meningioma gene-signature risk scores were calculated on an independent validation dataset from an outside institution. The gene-signature risk score remains correlated with WHO grade and with faster TTF among patients who recurred (TTF vs log(GS risk), P = .002, F-test). Meningiomas which did not recur are not plotted. B, The gene risk score remains significantly associated with worse LFFR (P = .0004, log-rank test) and compares favorably to WHO grade in stratifying patients by OS (P = .003 vs P = .10, log-rank test). C, The gene-signature risk score remains significantly prognostic for mortality (RR 1.86 per 0.1 increase, 95% CI 1.19-2.88) after adjusting for WHO grade on Cox regression.